Novel Plant Polysaccharides-based Adjuvant Development
In recent years, plant polysaccharides have attracted extensive attention in vaccine adjuvants due to their low toxicity, small side effects, and immune activity. CD BioGlyco is a carbohydrate-based adjuvant supplier. We provide customers with new plant polysaccharide-based adjuvant development services. Our powerful Glyco™ Vaccine Development Platform and first-class technical services have been recognized by many scientists. We are looking forward to being your indispensable experimental assistant in the field of adjuvant development.
Background
One of the current challenges in adjuvant research is to increase adjuvant activity while reducing toxicity. Polysaccharides derived from higher plants are relatively nontoxic and do not cause significant side effects, considered to be effective biological response modifiers. Studies have found that new plant polysaccharides have great potential in targeting specific cellular and humoral immunity. Meanwhile, plant polysaccharide adjuvant has good safety and tolerance in inducing cellular immunity. Therefore, more and more researchers are turning to plant polysaccharide adjuvants for use in pathogen and cancer vaccines.
Fig.1 Mechanisms of action of plant adjuvants. (Granell, 2011)
Adjuvant Properties of Novel Plant Polysaccharides
FP-1, a novel plant polysaccharide from Linum usitatissimum, induces the expression of tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and IL-12 in mouse macrophages. And it inhibits hepatitis B virus (HBV), considered an effective vaccine adjuvant. A polysaccharide PCP-I derived from Poria cocos enhances the immunogenicity and protection of anthrax vaccine formulations. Polysaccharide POL-P3b from Purslane improves the effectiveness of foot-and-mouth disease vaccine. The polysaccharide extracted from Alhagi pseudohagi is also a good candidate for adjuvant. In addition, researchers have also found polysaccharides in plants such as Trollius chinensis, Siberian Solomonseal, Astragalus, Paulownia tomentosa, and Angelica that are used as vaccine adjuvants.
Novel Plant Polysaccharides-based Adjuvant Development Services
Plants are a good source of novel polysaccharides. Plant polysaccharides have pharmacological effects such as anti-tumor, hypoglycemic, and immune regulation. Plant polysaccharides have demonstrated immunoadjuvant activity with low toxicity and fewer side effects. Therefore, novel plant polysaccharides have become the best choice for future vaccine adjuvants. CD BioGlyco provides polysaccharides adjuvant development services from various plant sources such as Trollius chinensis, Siberian Solomonseal, Astragalus, Paulownia tomentosa, Angelica, Linum usitatissimum, Poria cocos, Purslane, Actinidia eriantha, Rehmannia glutinosa, Isatis indigotica, Inulin, and Propolis, etc.
CD BioGlyco is a leader in carbohydrate adjuvant development. We are very pleased to share our knowledge and experience in adjuvant development to provide customers with professional, high-quality novel plant polysaccharides-based adjuvant development services. If you have an adjuvant development project, please contact us directly, and we will provide the customized experimental plan according to your needs.
References:
- Garcia-Vello, P.; et al. Carbohydrate-based adjuvants. Drug Discovery Today: Technologies. 2020, 35:57-68.
- Granell, A.; et al. In planta production of recombinant and indigenous adjuvants. Future Medicine Ltd. 2011.
